10 results about "Hepatitis B Surface Antigens" patented technology

The present disclosure relates to antibodies, and antigen binding fragments thereof, that can bind to the antigenic loop region of hepatitis B surface antigen (HBsAg) and can neutralize infection of both hepatitis B virus (HBV) and hepatitis delta virus (HDV). The present disclosure also relates to epitopes to which the antibodies and antigen binding fragments bind, as well as to fusion proteins that comprise the antigen binding fragments, and to nucleic acids that encode and cells that produce such antibodies and antibody fragments. In addition, the present disclosure relates to the use of the antibodies and antibody fragments of the present disclosure in the diagnosis, prophylaxis and treatment of hepatitis B and hepatitis D.

The present invention discloses an adenine-rich phosphorothioate oligonucleotide and its application in anti-hepatitis virus. Specifically, the present invention discloses a m AAC n A repetitive sequence-rich adenine phosphorothioate oligonucleotide (ARON) is used for inhibiting hepatitis B surface antigen (HBsAg) and for treating hepatitis B virus infection or hepatitis B virus / hepatitis D virus co-infection. The adenine phosphorothioate oligonucleotide (ARON) is 15-40 nucleotides in length and contains adenine nucleotides and cytosine nucleotides, wherein the content of adenine nucleotides exceeds 50%, has high antiviral activity and a sufficiently large safety window.

The invention relates to the technical field of medical information processing, and discloses a hepatitis B surface antigen track mode prompting method, device and equipment and a storage medium, the method comprises the following steps: obtaining hepatitis B surface antigen information obtained by multiple first objects through multiple times of detection, the first objects being chronic hepatitis B objects; obtaining a first grouping result output by a target group-based trajectory model, wherein the target group-based trajectory model is used for grouping the first objects based on the trajectory of the hepatitis B surface antigen information; based on the first grouping result, determining a hepatitis B surface antigen trajectory pattern corresponding to the first object in each group, one group corresponding to one hepatitis B surface antigen trajectory pattern; for the first object in the group, corresponding first prompt information is output, the first prompt information is used for indicating the hepatitis B surface antigen track mode of the first object, different hepatitis B surface antigen track modes correspond to different target states, and the target states are converted states. The invention can guide the development and improvement of medicines.

The present invention relates to an antibody against hepatitis B surface antigen (HBsAg), a nucleic acid molecule encoding the antibody, and a pharmaceutical composition comprising the antibody. The anti-HBsAg antibody disclosed by the invention can be combined with HBsAg in a pH-dependent manner, and has enhanced capability of combining with FcRn and Fc gamma R, remarkably enhanced antigen removal effect and prolonged half-life period.

This invention relates to a fusion antigen mRNA molecule, which encodes a protein comprising at least two of the following: hepatitis B surface antigen protein sHBsAg, hepatitis B core antigen protein Core, hepatitis B X antigen protein HBxAg, and hepatitis B preS1 antigen protein PreS1, preferably comprising hepatitis B surface antigen protein sHBsAg, hepatitis B core antigen protein, and hepatitis B PreS1 antigen protein, denoted as sHBsAg-Core-PreS1, and its amino acid sequence is shown in SEQ ID No. 17; the above-mentioned fusion antigen mRNA molecule can be prepared into an mRNA-LNP vaccine composition and used to treat chronic hepatitis B virus infection. The preferred sHBsAg-Core-PreS1 mRNA-LNP of this invention can normally express and present each encoded target antigen in vivo, and achieve cross-presentation, cross-activation and enhanced expression, inducing target antigen-specific humoral and cellular immune responses. It can also effectively overcome immune tolerance in a mouse model of chronic hepatitis B, and has excellent antiviral and immunotherapeutic effects. Compared with existing related therapeutic HBV mRNA-LNP vaccines, it effectively improves the immune tolerance breakthrough threshold, providing a candidate vaccine and a new immunotherapy strategy for the immunotherapy of patients with chronic HBV infection.

Provided herein are immune stimulating anti-HBsAg antibody conjugates, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of an HBV infection.

An african swine fever virus vaccine includes five groups of antigens in total, and each group is respectively obtained by constructing recombinant adenovirus vectors co-expressing four antigen genes of african swine fever virus, and packaged by 293TD37 cells. The four antigenic genes of African swine fever virus in each group are 1, P72, B602L, P30 and P54; 2, CP129Rubiqutin, MGF5L6L, CP312R, and MGF110-4L; 3, L8Lubiqutin, I215L, I73RHBsAgHBsAg and E146L; 4, EP402R, EP153R, I177L, and K205Rubiqutin; 5, F317L, A151R, P34, and pp62. The construction of the recombinant adenovirus vector for co-expression of four antigen genes of the african swine fever virus mainly includes: knocking out E1, E3, E2a and E4 genes of the adenovirus vector by CRISPR / cas9 technology, constructing an ORF6 / 7 expression frame of E4 in an E2a region, and constructing shuttle plasmids in E1 and E4 regions for appropriately expressing four antigen genes, thereby obtaining a completely new adenovirus vector.

A method of curing chronic hepatitis B infection in humans is provided, the method including administering to a subject in need thereof, an effective amount of one or both of an exogenous anti-HBs antibody or an anti-HBs antibody producing vector to reduce cellular and blood hepatitis B surface antigen (HBsAg), by providing a sustained elevated level of anti-HBs antibody in the subject.

The present disclosure relates to antibodies, and antigen binding fragments thereof, that can bind to the antigenic loop region of hepatitis B surface antigen (HBsAg) and can neutralize infection of both hepatitis B virus (HBV) and hepatitis delta virus (HDV). The present disclosure also relates to epitopes to which the antibodies and antigen binding fragments bind, as well as to fusion proteins that comprise the antigen binding fragments, and to nucleic acids that encode and cells that produce such antibodies and antibody fragments. In addition, the present disclosure relates to the use of the antibodies and antibody fragments of the present disclosure in the diagnosis, prophylaxis and treatment of hepatitis B and hepatitis D.

The present invention relates to the field of biomedicine, and in particular to an antigen-antibody complex for enhancing an immune response of a hepatitis B patient, a preparation method therefor, and a use thereof. An antigen-antibody complex formulation prepared from HBsAg and an anti-HBsAg monoclonal antibody is superior to an antigen-antibody complex formulation prepared from a polyclonal antibody in respect of sustained induction of an immune response of a chronic hepatitis B patient. An antigen-antibody complex that induces an immune response of a hepatitis B patient is developed for the first time. In the complex, a hepatitis B surface antigen binds to the anti-HBsAg monoclonal antibody, and the complex composed of the hepatitis B surface antigen and the anti-HBsAg monoclonal antibody which have a certain mass ratio can induce the immune response of the chronic hepatitis B patient, and can also prevent and / or treat chronic hepatitis B.